MMP-01: Pilot Study Evaluating Activity of the Combination of Anti-PD-1 Antibody With High Dose IL-2 in Metastatic Melanoma
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Interleukin-2 (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 18 Oct 2019 Status changed from recruiting to discontinued.
- 31 Aug 2018 Biomarkers information updated
- 09 May 2018 Planned End Date changed from 1 Apr 2022 to 1 May 2022.